North Carolina GLP-1 Lawsuit Overview
If you live in North Carolina and were diagnosed with NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) after taking a GLP-1 drug such as Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, or Rybelsus, you may be eligible to file a claim in the federal GLP-1 NAION MDL (MDL 3163).
All GLP-1 NAION claims — regardless of where the plaintiff lives — are consolidated in MDL 3163 in the Eastern District of Pennsylvania under Judge Karen Marston. You do not need to travel to Pennsylvania to file. Your local attorney can handle your case as part of the MDL.
3 Years
Discovery Rule May Apply
North Carolina Statute of Limitations Details
North Carolina generally applies a 3-year injury period with product-liability timing often influenced by accrual and repose doctrines.
Who Qualifies in North Carolina?
To file a GLP-1 NAION claim as a North Carolina resident, you generally need:
- A documented prescription for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or Trulicity
- An ophthalmologist's diagnosis of NAION or sudden optic nerve-related vision loss
- NAION developed during or after your GLP-1 drug use (not before)
- Filing within North Carolina's 3-year statute of limitations window
How the MDL Works for North Carolina Residents
Even though MDL 3163 is located in Pennsylvania, North Carolina residents can participate without traveling. Here's how:
- You hire a North Carolina-licensed attorney or a national mass tort firm
- Your case is filed in the MDL in Pennsylvania (or transferred there)
- All major MDL proceedings are handled by the Plaintiffs' Steering Committee
- You participate through your attorney, primarily via written correspondence and phone
- If your case goes to individual trial, it may be remanded to a federal court in North Carolina
North Carolina State Bar Resources
To find a licensed attorney in North Carolina, you can use the official state bar's attorney referral service:
Visit North Carolina State Bar →
Neighboring State Resources
Key Cities in North Carolina
GLP-1 drug users across North Carolina — including Charlotte, Raleigh, Greensboro, Durham, Winston-Salem — are eligible to participate in MDL 3163 regardless of their city.